{"prompt": "['Novartis', 'Confidential', 'Page 76', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '13', 'Appendix 1: Liver event and Laboratory trigger Definitions', 'and Follow-up Requirements', 'Table 13-1 Liver Event and Laboratory Trigger Definitions', 'Definition/ threshold', 'LIVER LABORATORY TRIGGERS', '3x ULN < ALT / AST < 5 x ULN', '1.5 X ULN < TBL < 2 X ULN', 'LIVER EVENTS', 'ALT or AST > 5 x ULN', 'ALP > 2 x ULN (in the absence of known bone pathology)', 'TBL > 2 x ULN (in the absence of known Gilbert syndrome)', 'ALT or AST > 3 x ULN and INR > 1.5', \"Potential Hy's Law cases (defined as ALT or AST > 3 x ULN and\", 'TBL > 2 x ULN [mainly conjugated fraction] without notable', 'increase in ALP to > 2 x ULN)', 'Any clinical event of jaundice (or equivalent term)', 'ALT or AST > 3 x ULN accompanied by (general) malaise, fatigue,', 'abdominal pain, nausea, or vomiting, or rash with eosinophilia', 'Any adverse event potentially indicative of a liver toxicity*', '*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related', 'conditions; the non-infectious hepatitis; the benign, malignant and unspecified liver neoplasms', 'TBL: total bilirubin; ULN: upper limit of normal', 'Table 13-2 Follow Up Requirements for Liver Events and Laboratory Triggers', 'Criteria', 'Actions required', 'Follow-up monitoring', \"Potential Hy's Law\", 'Discontinue the study treatment', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'casea', 'immediately', 'yGT until resolution\u00b0 (frequency at', 'Hospitalize, if clinically appropriate', 'investigator discretion)', 'Establish causality', 'Complete liver CRF', 'ALT or AST', '> 8 x ULN', 'Discontinue the study treatment', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'immediately', 'yGT until resolution (frequency at', 'Hospitalize if clinically appropriate', 'investigator discretion)', 'Establish causality', 'Complete liver CRF', '>', '3 x ULN and INR >', 'Discontinue the study treatment', 'ALT, AST, TBL, Alb, PT/INR, ALP and', '1.5', 'immediately', 'yGT until resolution\u00b0 (frequency at', 'Hospitalize, if clinically appropriate', 'investigator discretion)', 'Establish causality', 'Complete liver CRF', '> 5 to 8 x ULN', 'Repeat LFT within 48 hours', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'If elevation persists, continue follow-up', 'yGT until resolution (frequency at', 'monitoring', 'investigator discretion)', 'If elevation persists for more than 2', 'weeks, discontinue the study drug', 'Establish causality', 'Complete liver CRF']['Novartis', 'Confidential', 'Page 77', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Criteria', 'Actions required', 'Follow-up monitoring', '> 3 x ULN', 'Discontinue the study treatment', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'accompanied by', 'immediately', 'yGT until resolution (frequency at', 'symptoms', 'Hospitalize if clinically appropriate', 'investigator discretion)', 'Establish causality', 'Complete liver CRF', '> 3 to 5 x ULN', 'Repeat LFT within the next week', 'Investigator discretion', '(patient is', 'If elevation is confirmed, initiate close', 'Monitor LFT within 1 to 4 weeks', 'asymptomatic)', 'observation of the patient', 'ALP (isolated)', '> 2 x ULN (in the', 'Repeat LFT within 48 hours', 'Investigator discretion', 'absence of known', 'If elevation persists, establish causality', 'Monitor LFT within 1 to 4 weeks or at', 'bone pathology)', 'Complete liver CRF', 'next visit', 'TBL (isolated)', '> 2 x ULN (in the', 'Repeat LFT within 48 hours', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'absence of known', 'If elevation persists, discontinue the study', 'YGT until resolution (frequency at', 'Gilbert syndrome)', 'drug immediately', 'investigator discretion)', 'Hospitalize if clinically appropriate', 'Test for hemolysis (e.g., reticulocytes,', 'haptoglobin, unconjugated [indirect]', 'Establish causality', 'bilirubin)', 'Complete liver CRF', '> 1.5 to 2 x ULN', 'Repeat LFT within the next week', 'Investigator discretion', '(patient is', 'If elevation is confirmed, initiate close', 'Monitor LFT within 1 to 4 weeks or at', 'asymptomatic)', 'observation of the patient', 'next visit', 'Jaundice', 'Discontinue the study treatment', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'immediately', 'yGT until resolution\u00b0 (frequency at', 'Hospitalize the patient', 'investigator discretion)', 'Establish causality', 'Complete liver CRF', 'Any AE potentially', 'Consider study treatment interruption or', 'Investigator discretion', 'indicative of a liver', 'discontinuation', 'toxicity*', 'Hospitalization if clinically appropriate', 'Establish causality', 'Complete liver CRF', 'alevated ALT/AST > 3 x ULN and TBL > 2 x ULN but without notable increase in ALP to > 2 x ULN', 'b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia', 'Resolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at', 'three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6', 'months, (4) liver transplantation, and (5) death.']\n\n###\n\n", "completion": "END"}